<DOC>
	<DOCNO>NCT01186224</DOCNO>
	<brief_summary>To assess efficacy toxicity plerixafor ( AMD 3100 ) together granulocyte-colony stimulating factor ( G-CSF ) stem cell mobilisation , patient myeloma lymphoma require high dose chemotherapy stem cell rescue .</brief_summary>
	<brief_title>Plerixafor Harvesting And No Chemotherapy Transplantation Autologous STem Cells In Cancer ( PHANTASTIC )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Paraproteinemias</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>All following must satisfy : Aged 18 Able give inform write consent . Diagnosis EITHER multiple myeloma relate plasma cell dyscrasia , OR form lymphoma associate lymphoproliferative disease Autologous stem cell transplantation plan next course treatment . The patient previously undergone mobilisation attempt current transplant . Patients receive previous autologous transplant least 2 year previously eligible , long stem cell mobilisation attempt current transplant . No serious concomitant illness ( e.g . heart disease ) might preclude completion study . Creatinine clearance least 30 mls/min . Note dose reduction plerixafor require creatinine clearance 3050 mls/min ; see section 3.3/5.1/5.3 . Negative pregnancy test woman childbearing age . Unable give inform write consent Pregnancy lactate Creatinine clearance le 30 mls/min . Patients clearance low may still able receive plerixafor reduce dosage follow discussion trial coordinator , eligible entry trial . Any previous attempt mobilisation current transplant . Patients form leukaemia , INCLUDING PLASMA CELL LEUKAEMIA , eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>